CEPI COVID-19 booster study – recruiting now

An older man displaying three fingers to represent the three doses of the COVID-19 vaccine he has received.
  28 April 2022  Murdoch Children's Research Institute

To protect against COVID-19, most Victorians over the age of 12 years have received two doses of the COVID-19 vaccine (known as the primary vaccine course), mostly receiving the Pfizer or AstraZeneca vaccines.

It is becoming clear that the level of protection from COVID-19 infection following a primary course of any of the COVID-19 vaccines reduces after several months.

Our study aims to assess the immune responses of two different booster vaccines (Pfizer and Moderna), given either as a standard or fractional (reduced) dose, among people who have previously received two doses of either Pfizer or AstraZeneca vaccines. This information is crucial to designing optimal vaccine strategies in Australia and other countries that have used Pfizer or AstraZeneca as their primary two-dose schedule.

The Murdoch Children’s Research Institute (MCRI) is working in collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to conduct this study in Melbourne, where a total of 800 participants will be recruited.

You can participate if you are aged 18 years or older, have received two doses of either Pfizer or AstraZeneca COVID-19 vaccine and have not yet received a booster dose. You must be eligible for a booster dose as per advice from the Australian Technical Advisory Group on Immunisation (ATAGI), which is currently at least 3 months after your second dose.

Participants will receive either a Pfizer or Moderna booster dose at standard or fractional (reduced) dose and will be provided with their antibody test results.

To learn more about this study, visit the study page on the MCRI website.

A flyer (.pdf) is available to help promote the study.

For any other queries, please contact the study team at COVID.Booster@mcri.edu.au